Clinical Trial Update: A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification [Phase 4]

View source ↗

Summary

This Phase 4 trial compares peak aqueous penetration of Acuvail (ketorolac), Xibrom (bromfenac), and Nevanac (nepafenac) following phacoemulsification cataract …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cataracts

Drugs mentioned

• ACUVAIL (ketorolac tromethamine)
• Nevanac (nepafenac)
• Xibrom (bromfenac)

Snippet

Sponsor: Frank A. Bucci, Jr., M.D. | Conditions: Cataracts | Phase 4 | Status: COMPLETED | Results posted: 2011-08-26